QYQinghua Yi

Qinghua Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qinghua Yi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advance Microbiota Transplantation: A Novel Addition–Subtraction Paradigm for Optimising Faecal Microbiota Transplantation

    by Haojia Lin, Zelin Feng, Qiuyue Tu, Huizhen Li, Yanru Zhang, Xinyue Wei, Qinghua Yi, Hetong Zhang, Yu Wang, Xiaoqin Li, et al.

    Faecal microbiota transplantation (FMT) is highly effective for recurrent Clostridioides difficile infection but yields inconsistent benefits in chronic indications. As a crude whole‐microbiota transplant, FMT contains numerous undefined active components, complicating efforts to ensure treatment predictability and stability. Therefore, we propose Advance Microbiota Transplantation (AMT), a comprehensive, phase‐based hypothesis that employs an addition–subtraction strategy throughout the pre‐, peri‐ and post‐transplant stages. AMT comprises donor and recipient pre‐treatment, procedural optimisation and post‐transplant adjuvant interventions to mitigate donor variability, ecological resistance, procedural heterogeneity and unstable engraftment. Through a systematic synthesis of current evidence‐based FMT research, we explored how the addition–subtraction strategy can be operationalised to shape the AMT concept and define testable, phase‐specific levers, thereby providing a foundation for future clinical translation. In parallel, we appraised the reporting quality using the Preferred Reporting Items for Microbiotherapy (PRIM) and identified six persistently under‐reported items that limit the interpretability, comparability, and reproducibility of FMT research. This review aims to facilitate the integration of AMT into clinical practice.


  • Open Access

    Inflammatory-Driven Vitamin A Transport Dysfunction in Ulcerative Colitis

    by Zhe Zhou, Junming Miao, Yang Jing, Xiaojing Shi, Yifei Liu, Xinyue Wei, Zelin Feng, Huizhen Li, Qiuyue Tu, Hetong Zhang, et al.

    Background: Retinol-binding protein 4 (RBP4) is a vitamin A transport protein synthesized in the liver and also plays a crucial role in inflammation and immune regulation. Low serum vitamin A levels have been observed in both pediatric and adult patients with ulcerative colitis (UC). The association between serum vitamin A levels and serum RBP4 levels, as well as the underlying mechanism involved inimpaired vitamin A transport during inflammation in UC patients, has yet to been investigated. Methods: A validation cohort comprising 103 UC patients and 22 controls was analyzed. Serum RBP4 levels were measured using anenzyme-linked immunosorbent assay (ELISA), and correlations with vitamin A levels and disease severity wereassessed. A dextran sulfate sodium (DSS)-induced colitis mouse model was used to valuatehepatic RBP4 expression and inflammatory changes. Primary hepatocytes from C57BL/6 mice were exposed to inflammatory cytokines to assess the impact of these cytokines on RBP4 expression. Results: Serum vitamin A (p < 0.001) and RBP4 levels (p < 0.001) were significantly lower in UC patients compared to controls, exhibiting a pronounced decreasing trend as disease severity increased (vitamin A: p < 0.001; RBP4: p < 0.001), while vitamin A levels increased after effective treatment (p < 0.001). Hepatic RBP4 expression was reduced in the DSS-induced colitis model and negatively correlated with TNF-α, IL-6, and IL-17. Conclusions: Serum RBP4 levels are decreased in UC patients and negatively correlate with disease severity, possibly due to proinflammatory cytokine-induced suppression which might contribute to inflammation-driven vitamin A transport dysfunction.